BioNTech Investor Day Presentation Deck
Melanoma remains the deadliest skin cancer¹,2
Treatment options needed to address CPI failure in advanced melanoma
Incidence
+ 50%
Annual cases have
increased by nearly
50% to over
287,0001.2
Deaths
+ 20%
WHO predicts by
2025, number of
deaths will increase
by 20% ³
CPI R/R patients
~ 55%
patients refractory
to or relapse on CPI
treatment, leaving
them with limited
treatment options4
●
Ⓡ
NUM
mRNA cancer vaccines
Significant opportunity to improve
on standard of care
5-year survival for metastatic melanoma still only 29.8% 5
Frontline immunotherapy with CPI induces durable
responses in max. 45-50% of patients but with relatively
short PFS4
CPI resistant/refractory patients that fail to respond to
CPI or relapse after CPI have an especially poor
prognosis with survival as short as 6 months depending
on risk factors
CPI, checkpoint inhibitor; DoR, duration of response; mPFS, median progression free survival; ORR, overall response rate; R/R, refractory/resistant; WHO, World Health Organization.
1 Available at: https://www.melanomauk.org.uk/2020-melanoma-skin-cancer-report; 2 Global Cancer Observatory - 2018 data from 'Cancer Today'; 3 Global Cancer Observatory - projected 2025 data from
'Cancer Tomorrow'; 4 Larkin J. et al. N Engl J Med 2019; 381:1535-1546; 5 Available at: https://seer.cancer.gov/statfacts/html/melan.html (accessed August 06, 2021.
Advanced CPI R/R melanoma is a high medical need
population with highly unfavorable prognosis
BIONTECH
108View entire presentation